Chimeric canine anti-cd20 antibody

Abstract

The disclosure relates to caninized chimeric anti-CD20 antibodies to the canine protein CD20 and methods of use to treat certain disorders such as non-Hodgkins B-cell lymphoma in dogs.

We claim: 
     
         1 . An antibody comprising a light chain variable region (LCVR) whose amino acid sequence is that given in SEQ :ID NO: 12, and a heavy chain variable region (HCVR) whose amino acid sequence is that given in SEQ ID NO: 3. 
     
     
         2 . The antibody of  claim 1 , wherein the antibody specifically binds to canine CD20. 
     
     
         3 . An antibody comprising a light chain (LC) whose amino acid sequence is that given in SEQ ID No: 10, and a heavy chain (HC) whose amino acid sequence is that given in SEQ ID NO: 1. 
     
     
         4 . The antibody of  claim 3 , wherein the antibody specifically binds to canine CD20. 
     
     
         5 . An antibody comprising two light chains (LC) each having an amino acid sequence that is given in SEQ ID NO: 10, and two heavy chains (HC) each having an amino acid sequence that is given in SEQ ID NO: 1. 
     
     
         6 . The antibody of  claim 5 , wherein the antibody specifically binds to canine CD20. 
     
     
         7 . A method of treating lymphoma in a canine patient, comprising administering to a lymphoma cancer canine patient in need of such treatment an effective amount of an antibody comprising a light chain variable region (LCVR) whose amino acid sequence is that given in SEQ ID NO: 12, and a heavy chain variable region (HCVR) whose amino acid sequence is that given in SEQ ID NO: 3, wherein the antibody specifically binds to canine CD20. 
     
     
         8 . The method according to  claim 7  wherein the antibody comprises a light chain (LC) whose amino acid sequence is that given in SEQ ID NO: 10, and a heavy chain (HC) whose amino acid sequence is that given in SEQ ID NO: 1. 
     
     
         9 . The method according to  claim 7 , wherein the antibody is K9LO-133. 
     
     
         10 . A kit, comprising a pharmaceutical composition, comprising K9LO-133, with one or more pharmaceutically acceptable carriers, diluents, or excipients. 
     
     
         11 . An antibody comprising a light chain (LC) whose amino acid sequence is that given in SEQ ID NO: 10, and a heavy chain (HC) whose amino acid sequence is that given in SEQ :11) NO: 1 and wherein the antibody specifically binds to canine CD20, and wherein the antibody binds to protein A. 
     
     
         12 . Use of an antibody comprising a light chain variable region (LCVR) whose amino acid sequence is that given in SEQ ID NO: 12, and a heavy chain variable region (HCVR) whose amino acid sequence is that given in SEQ ID NO: 3, wherein the antibody specifically binds to canine CD20, for treating lymphoma in a canine patient. 
     
     
         13 . The use according to  claim 12  wherein the antibody comprises a light chain (LC) whose amino acid sequence is that given in SEQ ID NC): 10, and a heavy chain (HC) whose amino acid sequence is that given in SEQ ID NO: 1. 
     
     
         14 . The use according to  claim 12 , wherein the antibody is K9LO-133. 
     
     
         15 . An antibody comprising a light chain variable region (LCVR) whose amino acid sequence is that given in SEQ ID NO: 12, and a heavy chain variable region (HCVR) whose amino acid sequence is that given in SEQ ID NO: 3, wherein the antibody specifically binds to canine CD20, for use in treating lymphoma in a canine patient.